Cargando…

Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of Resveratrol, Lycopene, Vitamin C and anthocianin (Ixor(®))

INTRODUCTION: This is an observational study and the aim is to evaluate the effect of dietary supplements based on Resveratrol, Lycopene, Vitamin C and Anthocyanins (Ixor(®)) in reducing skin toxicity due to external beam radiotherapy in patients affected by breast cancer. MATERIALS AND METHODS: 71...

Descripción completa

Detalles Bibliográficos
Autores principales: Franco, Rossella Di, Calvanese, MariaGrazia, Murino, Paola, Manzo, Roberto, Guida, Cesare, Gennaro, Davide Di, Anania, Caterina, Ravo, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283474/
https://www.ncbi.nlm.nih.gov/pubmed/22289566
http://dx.doi.org/10.1186/1748-717X-7-12
_version_ 1782224192581664768
author Franco, Rossella Di
Calvanese, MariaGrazia
Murino, Paola
Manzo, Roberto
Guida, Cesare
Gennaro, Davide Di
Anania, Caterina
Ravo, Vincenzo
author_facet Franco, Rossella Di
Calvanese, MariaGrazia
Murino, Paola
Manzo, Roberto
Guida, Cesare
Gennaro, Davide Di
Anania, Caterina
Ravo, Vincenzo
author_sort Franco, Rossella Di
collection PubMed
description INTRODUCTION: This is an observational study and the aim is to evaluate the effect of dietary supplements based on Resveratrol, Lycopene, Vitamin C and Anthocyanins (Ixor(®)) in reducing skin toxicity due to external beam radiotherapy in patients affected by breast cancer. MATERIALS AND METHODS: 71 patients were enrolled and they were divided in two different groups: a control group (CG) of 41 patients treated with prophylactic topical therapy based on hyaluronic acid and topical steroid therapy in case of occurrence of radiodermatitis, and a Ixor-Group (IG) of 30 patients treated also with an oral therapy based on Resveratrol, Lycopene, Vitamin C and Anthocyanin (Ixor(®)) at a dose of 2 tablets/day, starting from 10 days before the radiation treatment until 10 days after the end of treatment. Skin toxicity has been related to PTV, to breast volume that received a radiation dose equal or lower than 107%, included between 107% and 110%, or greater than 110% of the prescribed dose. Moreover it's been studied the relationship between skin toxicity and the chemotherapy schedule used before treatment. We calculated in both groups the percentage of patients who had a skin toxicity of grade 2 or 3 (according to RTOG scale). Absolute risk reduction (ARR), relative risk (RR) and odds ratio (OR) have been calculated for each relationship. RESULTS: Control Group (CG) patients with a PTV > 500 ml presented skin toxicity G2 + G3 in 30% of cases, versus 25% of Ixor-Group (IG) [OR 0.77]. In patients with a PTV < 500 ml G2 + G3 toxicity was 0% in the IG compared to 18% in CG (OR 0.23). When Dmax was less than or equal to 107% of the prescribed dose skin toxicity was G2 + G3 in 12.5% in CG, versus 0% in IG (OR 0.73), instead when Dmax was included between 107 and 110% of the prescribed dose, G2 + G3 skin toxicity was 35% in CG and 21% in IG (OR 0.50). In patients undergoing chemotherapy with anthracyclines and taxanes, G2 + G3 toxicity was 27% in CG, against 20% in IG (OR 0.68). CONCLUSIONS: The protective effect of Resveratrol, Lycopene, Vitamin C and Anthocyanin (Ixor(®)) is more detected in patients with PTV < 500 ml, when Dmax reaches values lower or equal to 107%, but not exceeding 110% of the prescribed dose, and in patients undergoing adjuvant chemotherapy with anthracyclines and taxanes.
format Online
Article
Text
id pubmed-3283474
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32834742012-02-22 Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of Resveratrol, Lycopene, Vitamin C and anthocianin (Ixor(®)) Franco, Rossella Di Calvanese, MariaGrazia Murino, Paola Manzo, Roberto Guida, Cesare Gennaro, Davide Di Anania, Caterina Ravo, Vincenzo Radiat Oncol Methodology INTRODUCTION: This is an observational study and the aim is to evaluate the effect of dietary supplements based on Resveratrol, Lycopene, Vitamin C and Anthocyanins (Ixor(®)) in reducing skin toxicity due to external beam radiotherapy in patients affected by breast cancer. MATERIALS AND METHODS: 71 patients were enrolled and they were divided in two different groups: a control group (CG) of 41 patients treated with prophylactic topical therapy based on hyaluronic acid and topical steroid therapy in case of occurrence of radiodermatitis, and a Ixor-Group (IG) of 30 patients treated also with an oral therapy based on Resveratrol, Lycopene, Vitamin C and Anthocyanin (Ixor(®)) at a dose of 2 tablets/day, starting from 10 days before the radiation treatment until 10 days after the end of treatment. Skin toxicity has been related to PTV, to breast volume that received a radiation dose equal or lower than 107%, included between 107% and 110%, or greater than 110% of the prescribed dose. Moreover it's been studied the relationship between skin toxicity and the chemotherapy schedule used before treatment. We calculated in both groups the percentage of patients who had a skin toxicity of grade 2 or 3 (according to RTOG scale). Absolute risk reduction (ARR), relative risk (RR) and odds ratio (OR) have been calculated for each relationship. RESULTS: Control Group (CG) patients with a PTV > 500 ml presented skin toxicity G2 + G3 in 30% of cases, versus 25% of Ixor-Group (IG) [OR 0.77]. In patients with a PTV < 500 ml G2 + G3 toxicity was 0% in the IG compared to 18% in CG (OR 0.23). When Dmax was less than or equal to 107% of the prescribed dose skin toxicity was G2 + G3 in 12.5% in CG, versus 0% in IG (OR 0.73), instead when Dmax was included between 107 and 110% of the prescribed dose, G2 + G3 skin toxicity was 35% in CG and 21% in IG (OR 0.50). In patients undergoing chemotherapy with anthracyclines and taxanes, G2 + G3 toxicity was 27% in CG, against 20% in IG (OR 0.68). CONCLUSIONS: The protective effect of Resveratrol, Lycopene, Vitamin C and Anthocyanin (Ixor(®)) is more detected in patients with PTV < 500 ml, when Dmax reaches values lower or equal to 107%, but not exceeding 110% of the prescribed dose, and in patients undergoing adjuvant chemotherapy with anthracyclines and taxanes. BioMed Central 2012-01-30 /pmc/articles/PMC3283474/ /pubmed/22289566 http://dx.doi.org/10.1186/1748-717X-7-12 Text en Copyright ©2012 Franco et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methodology
Franco, Rossella Di
Calvanese, MariaGrazia
Murino, Paola
Manzo, Roberto
Guida, Cesare
Gennaro, Davide Di
Anania, Caterina
Ravo, Vincenzo
Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of Resveratrol, Lycopene, Vitamin C and anthocianin (Ixor(®))
title Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of Resveratrol, Lycopene, Vitamin C and anthocianin (Ixor(®))
title_full Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of Resveratrol, Lycopene, Vitamin C and anthocianin (Ixor(®))
title_fullStr Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of Resveratrol, Lycopene, Vitamin C and anthocianin (Ixor(®))
title_full_unstemmed Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of Resveratrol, Lycopene, Vitamin C and anthocianin (Ixor(®))
title_short Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of Resveratrol, Lycopene, Vitamin C and anthocianin (Ixor(®))
title_sort skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of resveratrol, lycopene, vitamin c and anthocianin (ixor(®))
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283474/
https://www.ncbi.nlm.nih.gov/pubmed/22289566
http://dx.doi.org/10.1186/1748-717X-7-12
work_keys_str_mv AT francorosselladi skintoxicityfromexternalbeamradiationtherapyinbreastcancerpatientsprotectiveeffectsofresveratrollycopenevitamincandanthocianinixor
AT calvanesemariagrazia skintoxicityfromexternalbeamradiationtherapyinbreastcancerpatientsprotectiveeffectsofresveratrollycopenevitamincandanthocianinixor
AT murinopaola skintoxicityfromexternalbeamradiationtherapyinbreastcancerpatientsprotectiveeffectsofresveratrollycopenevitamincandanthocianinixor
AT manzoroberto skintoxicityfromexternalbeamradiationtherapyinbreastcancerpatientsprotectiveeffectsofresveratrollycopenevitamincandanthocianinixor
AT guidacesare skintoxicityfromexternalbeamradiationtherapyinbreastcancerpatientsprotectiveeffectsofresveratrollycopenevitamincandanthocianinixor
AT gennarodavidedi skintoxicityfromexternalbeamradiationtherapyinbreastcancerpatientsprotectiveeffectsofresveratrollycopenevitamincandanthocianinixor
AT ananiacaterina skintoxicityfromexternalbeamradiationtherapyinbreastcancerpatientsprotectiveeffectsofresveratrollycopenevitamincandanthocianinixor
AT ravovincenzo skintoxicityfromexternalbeamradiationtherapyinbreastcancerpatientsprotectiveeffectsofresveratrollycopenevitamincandanthocianinixor